Drug-eluting stouts and glycoprotein IIb/IIIa inhibitors: Combination therapy for the futureLEON, Martin B; BAKHAI, Ameet.The American heart journal. 2003, Vol 146, Num 4, pp S13-S17, issn 0002-8703, SUPConference Paper

A primer for statistical analysis of clinical trialsDUOLAO WANG; BAKHAI, Ameet; MAFFULLI, Nicola et al.Arthroscopy (Print). 2003, Vol 19, Num 8, pp 874-881, issn 0749-8063, 8 p.Article

Can we afford to eliminate restenosis? Can we afford not to?GREENBERG, Dan; BAKHAI, Ameet; COHEN, David J et al.Journal of the American College of Cardiology. 2004, Vol 43, Num 4, pp 513-518, issn 0735-1097, 6 p.Article

A cost-utility analysis of clopidogrel in patients with ST elevation acute coronary syndromes in the UkKARNON, Jonathan; HOLMES, Mike W; WILLIAMS, Robert et al.International journal of cardiology. 2010, Vol 140, Num 3, pp 315-322, issn 0167-5273, 8 p.Article

Gender differences in the urinary excretion rates of cortisol and androgen metabolitesSHAMIM, Waqar; YOUSUFUDDIN, Mohammed; BAKHAI, Ameet et al.Annals of clinical biochemistry. 2000, Vol 37, pp 770-774, issn 0004-5632, 6Article

Rates and causes of death from non-ST elevation acute coronary syndromes: Ten year follow-up of the PRAIS-UK registryERDEM, Guliz; BAKHAI, Ameet; TANEJA, Anil K et al.International journal of cardiology. 2013, Vol 168, Num 1, pp 490-494, issn 0167-5273, 5 p.Article

Drug-eluting stents: an early systematic review to inform policyHILL, Ruaraidh A; DÜNDAR, Yenal; BAKHAI, Ameet et al.European heart journal. 2004, Vol 25, Num 11, pp 902-919, issn 0195-668X, 18 p.Article

Feasibility and cost of treatment with drug eluting stents of surgical candidates with multi-vessel coronary diseaseGRIFFITHS, Huw; BAKHAI, Ameet; WEST, Douglas et al.European journal of cardio-thoracic surgery. 2004, Vol 26, Num 3, pp 528-534, issn 1010-7940, 7 p.Conference Paper

Treatment patterns in acute coronary syndrome patients in the United Kingdom undergoing PCIBAKHAI, Ameet; INIGUEZ, Andres; FERRIERES, Jean et al.EuroIntervention. 2011, Vol 6, Num 8, pp 992-996, issn 1774-024X, 5 p.Article

National economic impact of tirofiban for unstable angina and myocardial infarction without ST elevation; example from the United KingdomBAKHAI, Ameet; FLATHER, Marcus D; COLLINSON, Julian R et al.International journal of cardiology. 2003, Vol 91, Num 2-3, pp 163-172, issn 0167-5273, 10 p.Article

Predictors, cost, and outcomes of patients with acute coronary syndrome who receive optimal secondary prevention therapy: Results from the antiplatelet treatment observational registries (APTOR)ZEYMER, Uwe; BERKENBOOM, Guy; COUFAL, Zdenek et al.International journal of cardiology. 2013, Vol 170, Num 2, pp 239-245, issn 0167-5273, 7 p.Article

Cost effectiveness of paclitaxel-eluting stents for patients undergoing percutaneous coronary revascularization : Results from the TAXUS-IV trial. CommentaryBAKHAI, Ameet; STONE, Gregg W; ELLIS, Stephen G et al.Journal of the American College of Cardiology. 2006, Vol 48, Num 2, pp 253-269, issn 0735-1097, 17 p.Article

Cost-effectiveness of coronary stenting and abciximab for patients with acute myocardial infarction: Results from the CADILLAC (Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications) trialBAKHAI, Ameet; STONE, Gregg W; COHEN, David J et al.Circulation (New York, N.Y.). 2003, Vol 108, Num 23, pp 2857-2863, issn 0009-7322, 7 p.Article

Conducting economic evaluations alongside multinational clinical trials : Toward a research consensusREED, Shelby D; ANSTROM, Kevin J; O'BRIEN, Bernie J et al.The American heart journal. 2005, Vol 149, Num 3, pp 434-443, issn 0002-8703, 10 p.Article

Management of non-ST-elevation acute coronary syndromes : how cost-effective are glycoprotein IIb/IIIA antagonists in the UK national health service?PALMER, Stephen; SCULPHER, Mark; HALL, Alistair et al.International journal of cardiology. 2005, Vol 100, Num 2, pp 229-240, issn 0167-5273, 12 p.Article

Fondaparinux versus Enoxaparin in non-ST-elevation acute coronary syndromes: Short-term cost and long-term cost-effectiveness using data from the Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators (OASIS-5) trialSCULPHER, Mark J; LOZANO-ORTEGA, Greta; SAMBROOK, Jennifer et al.The American heart journal. 2009, Vol 157, Num 5, pp 845-852, issn 0002-8703, 8 p.Article

Differences in the use of guideline-recommended therapies among 14 European countries in patients with acute coronary syndromes undergoing PCIZEYMER, Uwe; JAMES, Stefan; BAKHAI, Ameet et al.European journal of preventive cardiology (Print). 2013, Vol 20, Num 2, pp 218-228, issn 2047-4873, 11 p.Article

Feasibility and implications of an early discharge strategy after percutaneous intervention with abciximab in acute myocardial infarction (the CADILLAC trial)KANDZARI, David E; TCHENG, James E; CARROLL, John D et al.The American journal of cardiology. 2003, Vol 92, Num 7, pp 779-784, issn 0002-9149, 6 p.Article

Postoperative B-type Natriuretic Peptide for Prediction of Major Cardiac Events in Patients Undergoing Noncardiac Surgery: Systematic Review and Individual Patient Meta-analysisRODSETH, Reitze N; BICCARD, Bruce M; CHONG, Carol P. W et al.Anesthesiology (Philadelphia). 2013, Vol 119, Num 2, pp 270-283, issn 0003-3022, 14 p.Article

Economic Evaluation of bivalirudin with provisional glycoprotein IIb/IIIa inhibition versus heparin with routine glycoprotein IIb/IIIa inhibition for percutaneous coronary intervention: Results from the REPLACE-2 trial. CommentaryCOHEN, David J; LINCOFF, A. Michael; MARK, Daniel B et al.Journal of the American College of Cardiology. 2004, Vol 44, Num 9, pp 1792-1800, issn 0735-1097, 12 p.Article

Mortality following non-ST elevation acute coronary syndrome: 4 years follow-up of the prais UK Registry (Prospective Registry of Acute Ischaemic Syndromes in the UK)TANEJA, Anil K; COLLINSON, Julian; FLATHER, Marcus D et al.European heart journal. 2004, Vol 25, Num 22, pp 2013-2018, issn 0195-668X, 6 p.Article